Lymphangioleiomyomatosis (LAM) — Comprehensive MD Examination Answer

DEFINITION

EPIDEMIOLOGY

• Estimated prevalence: 4.9 per 1,000,000 women (sporadic LAM)
• Two forms:
  1. Sporadic LAM (S-LAM) — somatic mutations, primarily in the TSC2 gene
  2. TSC-LAM — occurs in ~30–40% of female patients with Tuberous Sclerosis Complex (TSC), an autosomal dominant disorder (incidence 1 in 6000 live births), caused by germline mutations in TSC1 or TSC2
• Rare in males (clinically significant disease much less frequent)
• Average life expectancy: 29 years from diagnosis (NHLBI Registry)
• 10-year and 20-year transplant-free survival: 85% and 64%, respectively

PATHOGENESIS

Molecular Basis

• TSC1 (hamartin) and TSC2 (tuberin) are tumour suppressor genes that regulate the mTOR (mammalian target of rapamycin) pathway
• Loss of TSC2 function → constitutive activation of mTORC1 → uncontrolled cell proliferation, survival, and abnormal smooth muscle-like LAM cell infiltration
• LAM is considered a low-grade neoplasm with metastatic properties — identical TSC2 mutations found in kidney AMLs and lung lesions of the same patient

Metastatic Model

• LAM cells arise from a remote origin (possibly uterus — supported by single-cell sequencing data)
• Spread occurs via lymphatic and haematogenous routes
• LAM cell clusters enter the venous circulation at the thoracic duct–jugular junction → disseminate to pulmonary capillary bed → invade/implant in lung
• Recurrence of LAM in transplanted donor lungs (from recipient LAM cells) supports this model

Role of Estrogen

• Marked female predominance; disease accelerates during pregnancy and slows after menopause
• LAM cells express estrogen and progesterone receptors
• Estrogen promotes LAM cell survival, migration, and invasion via non-genomic signaling (PI3K/Akt pathway)

Lymphangiogenesis

• LAM cells abundantly express lymphangiogenic markers: podoplanin (D2-40), LYVE-1, VEGFR-3, VEGF-C, VEGF-D
• Serum VEGF-D is elevated 3–8× above normal — key diagnostic and prognostic biomarker

PATHOLOGY

Gross

• Bilateral diffuse cystic change throughout both lungs
• Cysts range from 0.2–2 cm in diameter

Microscopy

• LAM nodules: proliferating smooth muscle-like cells in cyst walls, around airways, blood vessels, and lymphatics
• Two cell types:
  • Spindle-shaped cells (centre of nodules) — smaller
  • Epithelioid cells (periphery) — larger, with abundant cytoplasm
• Both react with antibodies to smooth muscle antigens (α-SMA) and with HMB-45 (melanocytic marker — key for diagnosis)
• Focal hemosiderin deposition (from alveolar hemorrhage)
• Lymphatic dilation and obstruction → chylous fluid

Immunohistochemistry

• HMB-45 positive — hallmark staining
• Smooth muscle actin (SMA) positive
• Desmin positive
• Estrogen and progesterone receptor positive

CLINICAL FEATURES

Symptoms

Lymphatic Complications

• Chylothorax (most common chylous complication)
• Chylous ascites, chyluria, chyloptysis
• Retroperitoneal/mediastinal/pelvic lymphangioleiomyomas (seen in 29% of S-LAM)
• Lymphadenopathy

Extrapulmonary Features

• Renal angiomyolipomas (AMLs): 32% in S-LAM; 93% in TSC-LAM
• Hepatic AMLs: rare in S-LAM (2%), more common in TSC-LAM (33%)
• TSC-LAM also shows: cortical tubers, giant cell astrocytomas, skin angiofibromas (adenoma sebaceum), ash-leaf macules, subungual fibromas, shagreen patches

Physical Examination

• Often normal early in disease
• Wheeze in ~30%
• Signs of pneumothorax or pleural effusion when present

INVESTIGATIONS

Pulmonary Function Tests (PFTs)

• Classic pattern: Obstructive defect (decreased FEV1/FVC)
• Reduced DLCO — often disproportionately low; most sensitive early marker
• Increased total lung capacity (TLC) and residual volume (RV) — hyperinflation (unlike most ILDs which show restriction)
• Air trapping on plethysmography
• Normal spirometry in 30–53% at diagnosis; progresses over time

Chest Imaging

• Bilateral diffuse reticulonodular infiltrates
• Cysts or bullae
• May show increased lung volumes (distinguishes from other ILDs)
• Pleural effusion (chylothorax)

• Diffuse, bilateral, round, thin-walled cysts of uniform distribution
• Cysts: typically <2 cm, well-circumscribed, scattered throughout all lung zones including costophrenic angles (unlike PLCH which spares costophrenic angles)
• No upper or lower lobe predominance (unlike Langerhans cell histiocytosis)
• Surrounding lung parenchyma is normal
• Cyst score on HRCT correlates with FEV1, RV, DLCO, and prognosis

• Renal and hepatic AMLs (fat-density within renal mass is pathognomonic of AML)
• Retroperitoneal/pelvic lymphangioleiomyomas

Serum Biomarker

• Serum VEGF-D ≥ 800 pg/mL — diagnostic of LAM when cystic lung disease is present on HRCT; unlikely in other cystic lung diseases

BAL

• May reveal hemosiderin-laden macrophages (occult alveolar hemorrhage)
• Chylous fluid (milky appearance)

DIAGNOSIS

1. Histopathologic/cytopathologic confirmation (HMB-45+ LAM cells)
2. Renal AML
3. Chylous effusion
4. Lymphangioleiomyoma
5. Serum VEGF-D ≥ 800 pg/mL
6. Tuberous sclerosis complex (TSC)

MANAGEMENT

Pharmacological

• Mechanism: Inhibits mTORC1 → reduces LAM cell proliferation
• MILES Trial (McCormack et al., NEJM 2011): Randomized, placebo-controlled trial. Sirolimus stabilized FEV1, improved quality of life and 6-minute walk distance; FEV1 declined in placebo group
• Dose: Start 2 mg/day; titrate to trough levels 5–15 ng/mL
• Indications: Abnormal/declining PFTs, significant symptoms, chylous complications, AML >3 cm
• Post-treatment: FEV1 decline resumes after stopping; hence considered chronic therapy
• Benefit persists regardless of TSC type, menopausal status, or race
• Everolimus: Alternative with shorter half-life (useful pre-transplant washout)

• Oophorectomy, progesterone, tamoxifen — no RCT evidence; not routinely recommended
• Avoid exogenous estrogen (OCP contraindicated)

• 17–25% have bronchodilator-responsive obstruction; trial is warranted

• Maintain SpO₂ ≥90% at rest, exertion, sleep

Management of Complications

General Recommendations

• Avoid air travel/diving/high altitude activities during pneumothorax risk periods
• Vaccinations: influenza, pneumococcal (13-valent and 23-valent); avoid live vaccines on mTOR inhibitors; recombinant shingles vaccine if on sirolimus
• Bone densitometry for patients on antiestrogen therapy
• Pregnancy: accelerates disease; not recommended in women with moderate-severe disease
• HRCT screening:
  • Women with spontaneous pneumothorax
  • Women with TSC (80% have cysts by age 30+)
• Pulmonary rehabilitation improves exercise capacity and quality of life

PROGNOSIS

• Highly variable; more favorable than initially reported
• Median transplant-free survival: 29 years from symptom onset, 23 years from diagnosis (NHLBI Registry)
• Adverse prognostic factors:
  • Low FEV1 or DLCO at diagnosis
  • Predominant cystic pattern over LAM cell infiltrate
  • LAM Histology Score (LHS)-2 or LHS-3 (>25% lung involvement)
  • Premenopausal status
  • High baseline serum VEGF-D
  • Hemosiderin-laden macrophages on biopsy
• Post-menopause: rate of decline in lung function slows
• Most patients die of respiratory failure; mean 10 years from symptom onset (pre-sirolimus era)

KEY POINTS FOR EXAM

1. LAM = neoplastic disease of smooth muscle-like cells; TSC2 mutation → mTOR pathway dysregulation
2. Exclusively/predominantly in premenopausal women; worsens with pregnancy/estrogen
3. Triad: Bilateral cystic lung disease + AML + Lymphatic complications
4. HRCT: Diffuse bilateral thin-walled cysts, uniform distribution, all lung zones
5. PFTs: Obstructive + increased TLC/RV (not restrictive — unlike other ILDs)
6. Biomarker: Serum VEGF-D ≥ 800 pg/mL is diagnostic
7. Histology: HMB-45 positive LAM cells are pathognomonic
8. Treatment: Sirolimus (mTOR inhibitor) stabilizes lung function (MILES trial)
9. Spontaneous pneumothorax in a non-smoking woman → prompt HRCT to rule out LAM
10. Lung transplant effective but LAM may recur in the donor lung from recipient cells